Venetoclax After TKI to Target Persisting Stem Cells in CML
Status:
Not yet recruiting
Trial end date:
2025-07-01
Target enrollment:
Participant gender:
Summary
There is currently no available treatment, capable to increase the rate of sustained deep
molecular remissions after TKI discontinuation in CML. Venetoclax could be such a drug. The
study will provide unprecedented biological insights on the effects of venetoclax in
controlling minimal residual stem cell disease induced by long-term prior TKI therapy. If the
study would be positive, the findings could become practice changing for patients in deep
molecular remission under TKI and willing to tolerate a temporary additional treatment.